Krystal Biotech Inc. (KRYS)
Krystal Biotech Statistics
Share Statistics
Krystal Biotech has 28.9M shares outstanding. The number of shares has increased by 0.87% in one year.
| Shares Outstanding | 28.9M |
| Shares Change (YoY) | 0.87% |
| Shares Change (QoQ) | 0.16% |
| Owned by Institutions (%) | 96.69% |
| Shares Floating | 24.7M |
| Failed to Deliver (FTD) Shares | 135 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 2.71M, so 9.41% of the outstanding shares have been sold short.
| Short Interest | 2.71M |
| Short % of Shares Out | 9.41% |
| Short % of Float | 12.41% |
| Short Ratio (days to cover) | 10.58 |
Valuation Ratios
The PE ratio is 50.24 and the forward PE ratio is 15.41. Krystal Biotech's PEG ratio is 0.07.
| PE Ratio | 50.24 |
| Forward PE | 15.41 |
| PS Ratio | 15.42 |
| Forward PS | 3.5 |
| PB Ratio | 4.73 |
| P/FCF Ratio | 37.58 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Krystal Biotech has an Enterprise Value (EV) of 4.14B.
| EV / Sales | 14.26 |
| EV / EBITDA | 37.68 |
| EV / EBIT | 33.56 |
| EV / FCF | 34.75 |
Financial Position
The company has a current ratio of 7.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.28 |
| Quick Ratio | 7.02 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 9.42% and Return on Invested Capital is 6.43%.
| Return on Equity | 9.42% |
| Return on Assets | 8.44% |
| Return on Invested Capital | 6.43% |
| Revenue Per Employee | $1.06M |
| Profits Per Employee | $324.21K |
| Employee Count | 275 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | 6.2M |
| Effective Tax Rate | 6.5% |
Stock Price Statistics
The stock price has increased by 2.96% in the last 52 weeks. The beta is 0.75, so Krystal Biotech's price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | 2.96% |
| 50-Day Moving Average | 174.55 |
| 200-Day Moving Average | 178.91 |
| Relative Strength Index (RSI) | 41.3 |
| Average Volume (20 Days) | 287.02K |
Income Statement
In the last 12 months, Krystal Biotech had revenue of 290.51M and earned 89.16M in profits. Earnings per share was 3.12.
| Revenue | 290.51M |
| Gross Profit | 270.45M |
| Operating Income | 65.69M |
| Net Income | 89.16M |
| EBITDA | 109.91M |
| EBIT | 103.19M |
| Earnings Per Share (EPS) | 3.12 |
Balance Sheet
The company has 344.87M in cash and 7.26M in debt, giving a net cash position of 337.6M.
| Cash & Cash Equivalents | 344.87M |
| Total Debt | 7.26M |
| Net Cash | 337.6M |
| Retained Earnings | -180.67M |
| Total Assets | 1.06B |
| Working Capital | 640.05M |
Cash Flow
In the last 12 months, operating cash flow was 123.42M and capital expenditures -4.24M, giving a free cash flow of 119.18M.
| Operating Cash Flow | 123.42M |
| Capital Expenditures | -4.24M |
| Free Cash Flow | 119.18M |
| FCF Per Share | 4.17 |
Margins
Gross margin is 93.09%, with operating and profit margins of 22.61% and 30.69%.
| Gross Margin | 93.09% |
| Operating Margin | 22.61% |
| Pretax Margin | 32.82% |
| Profit Margin | 30.69% |
| EBITDA Margin | 37.83% |
| EBIT Margin | 22.61% |
| FCF Margin | 41.02% |
Dividends & Yields
KRYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.99% |
| FCF Yield | 2.66% |
Analyst Forecast
The average price target for KRYS is $218, which is 34.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $218 |
| Price Target Difference | 34.7% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 27.74 |
| Piotroski F-Score | 6 |